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Introduction {#sec1}
============

Elicitation of broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) is thought to be a key component of a successful HIV-1 vaccine ([@bib14]). VRC01-class antibodies, which target the conserved CD4 receptor binding site (CD4bs), are among the broadest neutralizing antibodies. However, these bnAbs typically display high levels of somatic hypermutation (SHM) ([@bib13], [@bib17], [@bib47], [@bib54], [@bib57]) and often require years to develop during natural infection ([@bib29], [@bib34]). These features suggest that VRC01-class antibodies undergo a long and complex affinity maturation process ([@bib55]) and may be difficult to elicit by immunization.

VRC01-class antibodies have been isolated from several chronically HIV-infected individuals and differ by up to 42% in nucleotide sequence. However, antibodies of this class share common features ([@bib54], [@bib57]) ([@bib17], [@bib45]) including the use of a VH1-2 variable gene, a 5-residue LCDR3, and a short/flexible LCDR1. These shared features favor the rational design of immunogens to activate the precursors of VRC01-class bnAbs---so called germline-targeting immunogens ([@bib19], [@bib37]). Such immunogens have succeeded in eliciting narrowly neutralizing antibody responses with VRC01-class features in transgenic mouse models ([@bib8], [@bib11], [@bib20], [@bib38], [@bib50], [@bib51]). However, these responses lack the neutralization breadth associated with VRC01-class bnAbs isolated from chronic infection. Comparison between VRC01-class antibodies ([@bib8], [@bib19], [@bib37]) and subsequent design of minimally mutated VRC01-class antibodies ([@bib22]) highlighted the functional role of key "patches" of SHM that contribute to neutralization breadth and potency. The importance of these mutations was confirmed by comparing to the relatively strain-specific neutralizing DRVI07 antibody lineage, which harbored all the distinguishing features of VRC01-class antibodies except for the SHM in the light chain needed to accommodate the N276- and N462- glycans adjacent to the CD4bs ([@bib25]). These data indicate that accommodation of the glycans surrounding the CD4bs is a major hurdle for acquiring neutralization breadth that is typical for VRC01-class antibodies.

A detailed analysis of VRC01-class antibody development during infection has been limited by the rare nature of these responses during natural infection and the lack of longitudinal sampling of such responses. Furthermore, although germline-targeting immunogens have successfully fished out naive precursors B cells with VRC01-like features from HIV-naive individuals ([@bib21], [@bib16]), whether these precursors are capable of leading to bnAbs is not known. Moreover, there is no clear pathway for the rapid elicitation of VRC01-class lineages and it is not known whether key mutations need to be introduced in a particular order.

In this study, we describe and map the rapid development of VRC01-class bnAbs in a subtype C-infected Protocol C participant, PC063, with clear CD4bs-targeting broadly neutralizing plasma activity ([@bib29]). We report characterization of monoclonal antibodies isolated from this donor and outline the affinity maturation of the antibody lineage through next-generation sequencing and functional analyses. Overall, the elicitation and affinity maturation of VRC01-class antibodies in the PC063 donor challenges the notion that VRC01-class antibodies require high levels of somatic hypermutation and long periods of affinity maturation to gain neutralization breadth and potency. Additionally, we present data that suggests, in the case of the PCIN63 lineage, the presence of the N276 glycan adjacent to the CD4bs that commonly obstructs VRC01-class antibody binding might have offered favorable interactions to drive affinity maturation of this antibody lineage. The results of these findings have direct implications for HIV vaccine design strategies.

Results {#sec2}
=======

PCIN63 Antibodies Are Minimally Mutated VRC01-Class bnAbs {#sec2.1}
---------------------------------------------------------

Participant PC063 from the Protocol C cohort was shown previously to develop a CD4bs-directed bnAb response ([@bib29]). Broadly neutralizing antibody activity was first detected in PC063 plasma at 54 months post infection (mpi), approximately 2 years later than observed for most Protocol C broad neutralizers and reached peak neutralization at 72 mpi ([Figure 1](#fig1){ref-type="fig"}A). To isolate the antibodies contributing to the plasma neutralization breadth in this donor, we used the previously described recombinant HIV Env (rgp140F) WT and D368R (CD4bs epitope knock-out) proteins ([@bib33]). These proteins differentially adsorbed the broadly neutralizing activity from the plasma ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and were used as fluorophore-conjugated baits to sort CD4bs-specific memory B cells from peripheral blood mononuclear cells (PMBCs) samples collected at 66, 71, and 77 mpi ([Figure 1](#fig1){ref-type="fig"}A). Using this sort strategy, 18 mAbs, which define the PCIN63 lineage, were isolated ([Figure S1](#mmc1){ref-type="supplementary-material"}B).Figure 1PCIN63 Antibodies Define a Minimally Mutated VRC01-Class bnAb Lineage(A) Longitudinal plasma samples from donor PC063 were tested for neutralization against heterologous pseudoviruses. The percent of viruses neutralized (\> 50% inhibition of infectivity at the lowest plasma dilution, 1:50) from a cross-clade (A, B, C) 37-virus panel is shown as shaded blue bars. The blue line represents the neutralization score calculated for each sample and taking into account breadth and potency (see [@bib29]). The evolution of the viral load (red circles) in the plasma is also plotted. The time points at which PCIN63 antibodies were isolated are indicated by antibody symbols. See also [Figure S1](#mmc1){ref-type="supplementary-material"}A and S1B.(B) Comparison of CD4bs Abs genetic characteristics. Antibodies are listed and color-coded by classes as defined in Zhou et al., 2016: PCIN63 (Black), DRVI07 (Violet), VRC01-class bnAbs (Blue), HCDR3 dominated bnAbs (Red), VH1-46+ bnAbs (Brown). Top left inlet shows heavy (VH) and light chains (VL) putative V-genes nucleotide variation from IMGT database reference (% SHM). Middle left inlet shows length the HCDR3s, with mean ± SEM showed as lines. Bottom left inlet shows heterologous neutralization breadth (coverage in percentage of viruses neutralized) as reported in CATNAP database ([www.hiv.lanl.gov/content/immunology/neutralizing_ab_resources.html](http://www.hiv.lanl.gov/content/immunology/neutralizing_ab_resources.html){#interref0010}) and heavy chains (VH) V-genes nucleotide variation from IMGT database reference (percentage of SHM). Top right inlet shows light chain V-gene usage. Bottom right inlet shows logogram of the LCDR3 amino acid sequences for PCIN63 and other VRC01-class Abs. Residues common or unique to each category are colored in blue and red, respectively. See also [Figure S1](#mmc1){ref-type="supplementary-material"}C, S1D, and [S2](#mmc1){ref-type="supplementary-material"}.(C) Neutralization breadth (percentage of virus neutralized) is plotted as a function of potency (neutralization IC~50~ in μg/mL) of the indicated antibodies on a 120-virus panel ([@bib48]). See also [Tables S1--S4](#mmc1){ref-type="supplementary-material"}. Data are representative of at least two experiments.

PCIN63 Abs derive from IGHV1-2^∗^02/IGHJ5^∗^02 and IGKV1-5^∗^03/IGKJ1^∗^01 genes, and exhibit characteristic features of VRC01-class bnAbs, including a 5-residue LCDR3 QxxEx motif, a flexible Gly-rich LCDR1 and a 15-residue HCDR3 containing a WxxxDx motif upstream of HFR4 ([Figure 1](#fig1){ref-type="fig"}B, [S1](#mmc1){ref-type="supplementary-material"}C, S1D, [S2](#mmc1){ref-type="supplementary-material"}). Importantly, the SHM frequency of the PCIN63 lineage ranges from 9.6% to 16.0% (*V*~*H*~*+J*~*H*~) and from 10.0% to 13.7% (*V*~*K*~*+J*~*K*~) nucleotide mutation for the heavy (HC) and light (LC) chains, respectively, which is 2- to 3-fold lower than other VRC01-class bnAbs ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}C). Based on an alignment of PCIN63 mAbs amino acid sequences, the SHMs for this lineage accumulated at positions previously shown to be key epitope contact residues for the VRC01-class of bnAbs. These include mutations in HCDR1 and HCDR2, which are important for high-affinity binding to the gp120-Loop D and CD4bs-loop, and mutations in LCDR1 and LFR3 which reduce the steric clash with the N276- and N462-glycans on Env ([Figure S2](#mmc1){ref-type="supplementary-material"}) ([@bib57], [@bib22]). Moreover, the neutralization breadth of PCIN63 bnAbs is equivalent to VRC01 on a large cross-clade panel of pseudoviruses (N = 134) despite lower mutation frequencies ([Figures 1](#fig1){ref-type="fig"}B, 1C, [Tables S1](#mmc1){ref-type="supplementary-material"}-[S4](#mmc1){ref-type="supplementary-material"}). In fact, SHM in PCIN63 mAbs matched closely that of an engineered variant of mAb 12A21 designed to have the minimal set of SHM required for broadly neutralizing activity (min12A21) ([Figure S2](#mmc1){ref-type="supplementary-material"}) ([@bib22]). The identification of PCIN63 Abs thus challenges previous notions that high levels of SHM and prolonged affinity maturation are required for neutralization breadth and potency.

The Rapid Development of the PCIN63 bnAb Lineage Is Not Due to High Naive B Cell Precursor Frequency Nor Biased AID Motifs {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------

The development of VRC01-class antibodies responses is rare compared to bnAbs targeting other epitopes ([@bib31], [@bib53], [@bib34], [@bib29], [@bib44]). To determine whether the elicitation of VRC01-class antibodies in this donor was favored because of a higher frequency of VRC01-class precursors, we performed next-generation sequencing (NGS) of the naive peripheral B cell repertoire. The frequency of 5-residue LCDR3 B cells in the naive repertoire of PC063 was found to be slightly higher compared to HIV-naive donors from the United States (California) but similar to HIV-negative individuals from other African Protocol C sites ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

We next performed NGS on the peripheral IgG^+^ B cell repertoire to determine whether the low frequency of SHM observed for PCIN63 might have been associated with the presence or absence of biased AID motifs in the antibody lineage sequences that would favor affinity maturation. A total of 17 time points between 4 and 77 mpi were processed to generate unpaired heavy-chain and light-chain sequences ([Figure S3](#mmc1){ref-type="supplementary-material"}). The PCIN63 lineage was first detected at 40 mpi with progressive accumulation of nucleotide mutations that plateaued at 67 mpi ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Although the emergence of the PCIN63 bnAb lineage in PC063 occurred almost 2--3 years later than other bnAb lineages from published co-evolution studies targeting the CD4bs (CH235, non-VRC01-class) ([@bib3]), as well as other epitopes, the time required to reach maximum plasma breadth was overall similar ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B). Delayed onset (between 37--42 mpi) and fast maturation (14--19 mpi) to breadth was also reported for the DH270, which is a V3-glycan targeting lineage ([@bib4]). While comparison between independent studies is difficult to do accurately and plasma breadth does not necessarily correlate with frequency of SHM in the bnAb lineage, we verified that our estimation of time to maturation was overall consistent with the time to acquire some neutralization breadth in the earliest mAbs isolated from these lineages. We next evaluated whether the regions encoding for key contacts to HIV Env had an enrichment of AID hotspots that might have favored this rapid and highly focused affinity mutation to gain neutralization breadth, but no significant enrichments were found ([@bib43], See methods). Overall, despite the relatively rapid development of VRC01-class antibodies in the PC063 donor, high precursor frequencies or biased AID motifs that might have accelerated affinity maturation and selection does not appear to be driving factors.Figure 2SHM Motifs Are Selected Sequentially in the PCIN63 bnAb LineagePC063 IgG libraries prepared from total PBMCs (a single vial of 10 million cells per time point) were amplified with IgG-specific primers for all human VH gene families. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.(A) Comparison of the PCIN63 Ab lineage (Blue) development kinetics with other bnAbs lineages isolated as reported in original publications. Time to maturation (Mat.) is defined as the time between first detection of the lineage in the periphery (Init.) and peak neutralization breadth in plasma. See also [Figure S3](#mmc1){ref-type="supplementary-material"}B.(B) Delineation of PCIN63 Ab heavy (HC) and light (KC) chains V-segments SHM motifs (gray) on amino-acid sequences of PCIN63-71I and compared to mature VRC01, minVRC01, 12A21, and min12A21 and respective germlines. Residues varying from VH1-2 and VL putative germlines are indicated by a single letter code.(C and D) Longitudinal frequency of PCIN63 Ab lineage NGS sequences containing 1--5 residues mutated from germline motif to any of the amino-acid found in the isolated mature PCIN63 Abs. (C) Left panel shows motifs containing the same number of SHMs but varying in amino-acid sequence are separated by white lines within each shade of the motif-coded color. Motifs are arranged from top to bottom in chronological order of selection, i.e., time first mutation is detected for this motif. Right panel shows logogram representing the distribution of amino-acids at each position of the motif for the isolated mature PCIN63 Abs, the entire PCIN63 lineage NGS sequences and random Ab sequences from the same NGS dataset. Germline residues are indicated in black while mutated amino-acids found in the isolated matured PCIN63 Abs are colored using the pattern defined in (B).(D) Motifs are grouped based on the time for all motif residues to be mutated (Thick line).(E) Detail of LCDR1-Motif\#4 evolution showing the dynamics for the six dominant versions (see also [Figure S3](#mmc1){ref-type="supplementary-material"}E).

Longitudinal Sequence Analysis Identifies the Emergence of SHM Motifs Associated with Neutralization {#sec2.3}
----------------------------------------------------------------------------------------------------

Longitudinal evaluation of antibody lineages in natural infection can provide information on the order that SHM accumulates, which can then inform rational vaccine strategies to elicit a similar sequence of events. Accordingly, for PC063, detailed analysis of SHM selection pathways could serve as template for elicitation of VRC01-class Abs. Thus, we tracked the emergence and evolution of seven PCIN63 SHM motifs over the course of infection ([Figure 2](#fig2){ref-type="fig"}B). These motifs were selected based on previous studies identifying the minimal SHM required for VRC01 and 12A21 broad neutralization ([@bib22]). HCDR2-motif \#2 (contacting CD4bs-loop) and LCDR2-motif\#5 were first selected for, with mutations detected in nearly all sequences at month 40 at the emergence of the lineage ([Figure 2](#fig2){ref-type="fig"}C). Selection of HCDR1-motif\#1 (stabilizing HCDR2) and HFWR3-motif\#3 (contacting V5 loop) residues quickly followed at month 42, then LCDR1-motif\#4 (adaptation to N276-glycan) at 44 mpi and finally HFWR3-motif\#6 (adaptation to N276-glycan) and LCDR3-motif\#7 (contacting Loop D) at 49 mpi ([Figure 2](#fig2){ref-type="fig"}C). Both HCDR2-motif \#2 and HCDR1-motif\#1 sampled a diversity of mutations between months 42 and 55 before converging on a final set of mutations at month 55 and month 66, respectively. In contrast, for LCDR2-motif\#5 and HFWR3-motif\#3, the sequences rapidly converged at month 44 to a predominant sequence, which then persisted through month 74. While LCDR3-motif\#7 sampled several sequences before convergence at month 66, the other sets of mutations in the light chain, LCDR1-motif\#4 and LFWR3-motif\#6, converged rapidly without sampling different combinations of mutations.

Another representation of the data is presented in [Figure 2](#fig2){ref-type="fig"}D, which emphasizes when each SHM sequence motif fully converged to the affinity-mature SHM sequence. Globally, there appears to be three phases, early convergence for HCDR2-motif\#3 and LCDR2-motif\#5, intermediate convergence for HCDR2-motif\#2 and LFWR3-motif\#6 and late convergence for HCDR1-motif\#1, LCDR1-motif\#4, LCDR3-motif\#7 ([Figures 2](#fig2){ref-type="fig"}D and 2E). Overall, these results convey a complex affinity maturation process where different sequences are sampled for each SHM motif that then become fixed at different time points, in response to changes in the autologous virus swarm over time.

The PCIN63-UCA Does Not Bind to Env Proteins from Time Points Preceding Initiation of the Lineage {#sec2.4}
-------------------------------------------------------------------------------------------------

To better define the affinity maturation pathway for the PCIN63 lineage, we next determined the PCIN63 unmutated common ancestor (UCA). For the HC, an unmutated common ancestor (PCIN63-UCA-HC) was identified from the 40 mpi time point. However, for the light chain, lineage assignment based solely on V~K~+J~K~ gene usage and 5-residue LCDR3 criteria identified 18 unmutated putative precursor light chain sequences from the NGS dataset. The most frequent putative unmutated light chain sequence had an LCDR3 with amino-acid sequence QQSEA and was named PCIN63-UCA-KC1 ([Figure 3](#fig3){ref-type="fig"}A). The second most frequent unmutated light chain sequence with matching V~K~+J~K~ genes had an LCDR3 with amino-acid sequence QLYET, similar to the LCDR3 of the least mutated PCIN63-light chain sequences found at 40 mpi and was named PCIN63-UCA-KC2 ([Figure 3](#fig3){ref-type="fig"}A). To functionally characterize these putative UCAs, all 18 light chain variants were subsequently paired with the PCIN63-UCA-HC (UCA1-UCA18) and first tested for binding to VRC01-class germline targeting immunogens ([Figure 3](#fig3){ref-type="fig"}B). Only three Abs, including UCA2 but not UCA1, bound to eOD-GT8 with affinities lower to several recently described putative VRC01-class bnAb precursors ([@bib16]).Figure 3The Majority of Putative PCIN63 UCAs Do Not Bind eOD-GT8(A) Identification of PCIN63 lineage precursor sequences. The CDR3 of putative PCIN63-UCA NGS sequences (100% identity to PCIN63 Abs HC and LC germline V+J genes) are aligned with IMGT V~H~1-2^∗^02, D~H~6^∗^13, J~H~5^∗^03, Vκ1-5^∗^03, and Jκ1^∗^01 germline genes sequences. The N regions of the junctions are indicated. For putative PCIN63-UCA-KCs, the number of sequences (\# seq) found in the NGS dataset and the corresponding LCDR3 amino-acid sequences (right) are also indicated. Residues previously described as important for binding to the HIV Env CD4bs are colored in red.(B) Binding affinity of PCIN63 mature and putative UCA Abs and VRC01-class inferred germline (VRC01, VRC03, VRC07, 12A12, 12A21, 3BNC60, 3BNC117, VRC-PG04, VRC-CH31) and mature Abs (minVRC01, VRC01, VRC03, VRC07, VRC23, VRC27, 12A12, min12A21, 12A21, 3BNC117, VRC-PG19, VRC-CH31, VRC-N6) for the indicated previously described VH1-2 germline targeting immunogens, as measured by SPR. Data are representative of at least two experiments.

We next determined whether the PCIN63-UCA variants could bind to autologous envelope sequences isolated from the PC063 donor. Autologous envelopes were sequenced by NGS and single genome amplification (SGA) at each time point before 40 mpi ([Figure S4](#mmc1){ref-type="supplementary-material"}A). As described for other donors, PC063 Env variants became increasingly resistant to PCIN63 mAbs as mutations accumulated in loop D, CD4bs loop, and V5 loops, resulting in complete escape at month-61 ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Notably, among the set of sequences there was one rare virus variant isolated at 28 months post infection (M28cH1), lacking both the N276- and N462-glycans. As described previously, these glycans surround the CD4bs and are thought to obstruct binding of VRC01-class antibodies. However, none of the putative PCIN63-UCA Abs neutralized any of the autologous Env clones tested ([Figure S4](#mmc1){ref-type="supplementary-material"}C) and no binding could be detected to the corresponding gp120 proteins captured from lysed pseudovirions or to recombinant gp120 from representative Env clones ([Figure S4](#mmc1){ref-type="supplementary-material"}C), although, Env variants from 28 and 33 mpi had poor expression and therefore could not be evaluated. Overall, despite the availability of longitudinal sampling, UCA determination for this lineage remains partially ambiguous and the Env variants that triggered the PCIN63 Ab lineage is yet to be confirmed.

Autologous Adaptation to the N276-Glycan Is Associated with Heterologous Neutralization {#sec2.5}
---------------------------------------------------------------------------------------

Accommodation of the N276 glycan near the CD4bs is arguably the primary obstacle in eliciting VRC01-class responses. To determine at which point this occurred in the PC63 lineage, we next systematically evaluated the functional contributions of each SHM motif to neutralization breadth and potency. We generated PCIN63-UCA/71I chimeric antibody variants containing or lacking individual SHM motifs and evaluated each variant for neutralization against N276-glycan bearing or lacking autologous viruses as well as against a global heterologous 12-virus panel ([@bib9]) ([Figure 4](#fig4){ref-type="fig"}).Figure 4SHM Motifs in HCDR2, LCDR1, and LFWR3 Are Sufficient for Autologous Neutralization of N276-glycan Bearing Viral VariantsChimeric Abs were tested for neutralization of the indicated WT and N276A autologous Env clones sensitive to neutralization by PCIN63-71I and against the global 12-virus panel ([@bib9]). Autologous neutralization IC~50~ are plotted with symbols according to the legend, and neutralization breadth (percentage of viruses neutralized) on the global panel is indicated with a red line.(A) PCIN63-71I HC were either introduced into the PCIN63-UCA-HC (mut) or reverted to germline (rev). SHM motifs are color-coded as in [Figure 2](#fig2){ref-type="fig"}B and their position is indicated with diagrams. Mutated constructs were paired with WT PCIN63-UCA-KC1 (left), PCIN63-UCA-KC2 (middle), or PCIN63-71I (right) LC and tested for neutralization.(B) PCIN63-71I-KC SHM motifs (as defined in [Figure 2](#fig2){ref-type="fig"}B) were introduced into the PCIN63-UCA-KC2, individually or in combination. Motifs are color-coded and their sequence position is indicated with a diagram. Mutated constructs were paired with WT PCIN63-UCA (left), PCIN63-UCA+Motif\#2+Motif\#3 (middle) or PCIN63-71I (right) HC. See also [Figure S5](#mmc1){ref-type="supplementary-material"}. Data are representative of at least two experiments.

Pairing the UCA-HC variants with the mature 71I-KC resulted in cross-neutralization of autologous viruses, particularly when HCDR2-motif\#2 was introduced to the UCA-HC ([Figure 4](#fig4){ref-type="fig"}A, right). The combined LC SHMs alone allowed weaker neutralization of autologous Env lacking the N276-glycan than N276-bearing clones except when paired with the HCDR2-motif\#2. In contrast, the UCA-KC2 variants paired with the mature 71I-HC predominantly neutralized viruses lacking the N276 glycan. These observations not only confirm the critical role of LC mutations in accommodating the N276-glycan but also suggest direct dependence on this glycan for binding of early PCIN63 intermediates to autologous Envs. Overall, pairing the UCA/71I-HC variants with the UCA-KC2 yielded broader autologous neutralization than pairing with UCA-KC1 ([Figures 4](#fig4){ref-type="fig"}, [S5](#mmc1){ref-type="supplementary-material"}). This observation not only support UCA2 as the natural precursor of the PCIN63 lineage but also confirms an important role for the LCDR3 in elicitation of VRC01-class lineages.

Pairing the UCA-KC2 variants with an intermediate HC containing only HCDR2-motif\#2 and HFWR3-motif\#3 highlighted the co-dependence of LCDR1-motif4 and LFWR3-motif\#6 for neutralization of autologous viruses with PNGS at position N276, with a critical role for D32~LC~ in LCDR1-motif4 ([Figure S4](#mmc1){ref-type="supplementary-material"}B, middle). The detection of autologous M28cH1 neutralization by almost all Ab variants containing at least one SHM motif suggests it may indeed have been the eliciting variant.

The absence of individual SHM motifs in either the HC or the KC had minimal effects on autologous neutralization when the variants were paired with affinity-mature KC or HC, respectively, indicating redundancy across the SHM motifs for epitope recognition. Although heterologous neutralization was overall correlated with autologous neutralization of N276-glycan bearing viruses, the absence of individual SHM motifs had greater impact on heterologous neutralization, which was most significantly reduced in absence of LCDR1-motif\#4. In summary, SHM in HCDR2-motif\#2, LCDR1-motif\#4 and LFWR3-motif\#6 are sufficient for autologous neutralization of variant bearing the N276-glycan by PCIN63 Abs.

PCIN63 bnAbs Engage the N276-Glycan of Some Env Strains {#sec2.6}
-------------------------------------------------------

To better understand how the PCIN63 antibody lineage might interact with the N276 and other surrounding glycans, we next tested neutralization against heterologous viruses and their corresponding N276A mutants. The data revealed a hierarchy in the importance of glycans for neutralization by PCIN63 Abs, with N276 ≥ N197 \> N262 ≈N301 \> N462/N463 \> N448 ([Figure S6](#mmc1){ref-type="supplementary-material"}). This trend is generally consistent with the effects observed for other VRC01-class bnAbs, particularly 12A21 and other Abs bearing a glycine-rich LCDR1 loop (VRC23, VRC27, VRC-CH31) with the exception of VRC-N6 ([Figure S6](#mmc1){ref-type="supplementary-material"}, Table S5). We also observed significant variation between viral strains in their sensitivity to PCIN63 neutralization, as well as between PCIN63 mAbs in their ability to neutralize a given viral strain ([Figure 5](#fig5){ref-type="fig"}A). These variations were still apparent, although to a lesser extent, when pseudoviruses were produced in GnT I^−/−^ cells (293-S) yielding predominantly Man5 glycans on HIV Env ([Figure 5](#fig5){ref-type="fig"}A) ([@bib10]). The negative effect of glycan removal on neutralization for some viral strains by PCIN63 Abs was greater for N276 than other glycans and suggests that the Abs may directly depend on the N276-glycan for binding or neutralization in the context of some Env strains such as JR-CSF ([Figure 5](#fig5){ref-type="fig"}A). We evaluated other components of the epitope including surrounding glycans as well as key contact residues on Env and observed a general trend toward dependence on the N276-glycan when other obstructive features are present (JR-CSF) but accommodation of the N276 glycan when surrounding obstructive features are missing (JR-FL), such as the N461-glycan and the lack of N197- and N234-glycans ([Figure 5](#fig5){ref-type="fig"}A). We next determined whether there were shared motifs that lead to dependence or accommodation of the N276 glycan. An alignment of the PCIN63 antibody sequences that are or are not dependent on the N276-glycan revealed that the subset of PCIN63 antibodies that accommodate the N276 glycan share similar sequence features as the 12A21 antibody ([Figure 5](#fig5){ref-type="fig"}B). The N276-glycan dependent PCIN63 Abs carried SHM motifs possibly sub-optimal for high-affinity contacts with the CD4bs loop (non-aromatic residue N54~HC~) and V5 loop (Y61~HC~), while N276-glycan accommodating PCIN63 mAbs displayed a fourth Gly residues in LCDR1-motif\#4 (G34~LC~) and a more canonical LCDR3-motif\#7 with aromatic residues at position 91 and 97 optimal for loop D and V5 loop binding ([Figure 5](#fig5){ref-type="fig"}B). Additionally, all PCIN63 mAbs also carried R/W19~HC~ and E/D76~HC~ mutations possibly involved in N197-glycan interactions. Further corroborating the difference in antibody subsets, we also observed that PCIN63 Abs with N276-glycan dependent or accommodating phenotypes clustered in separate branches of the lineage phylogenetic trees suggesting divergent evolution in response to the N276-glycan for this lineage ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Overall, these observations suggest a greater dependence on direct contact with the N276-glycan when the CD4bs loop is less accessible and Env protein contacts sub-optimal.Figure 5Neutralization of PCIN63 and Other VRC01-Class Antibodies Is Strain-Specifically N276-Glycan Dependent(A) Fold decrease in neutralization IC~50~ of PCIN63 Abs (lower panel) and the listed VRC01-class Abs (upper panel) for N276A mutant of the indicated pseudotyped Env strains produced in 293-T or 293-S (GtnI^−/−^) cells compared to WT. The geomean with SD are shown. Relevant features of the selected Env strains are indicated above. Symbols are color-coded according to the permissive (blue) versus obstructive (red) potential regarding access to the CD4bs. See also [Figure S6](#mmc1){ref-type="supplementary-material"}. Data are representative of at least two experiments.(B) Logogram of the PCIN63 SHM motifs amino acid sequences for PCIN63 Abs segregated according to their sensitivity to N276-glycan removal (A) and compared to corresponding sequences of 12A12, 12A21, and min12A21 Abs. Residues common to 12A21 and PCIN63 N276-glycan accommodating Abs are colored in red. Residues shared between 12A21 and all PCIN63 Abs are colored in blue. SHM motifs are color-coded as in [Figure 2](#fig2){ref-type="fig"} and their position is indicated with diagrams. See also [Figures S2, S6](#mmc1){ref-type="supplementary-material"}, [Table S5](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

The exceptional breadth of VRC01-class bnAbs and their commonly shared features have long made them favored targets for rational vaccine design ([@bib54], [@bib57]). Despite major progress in the isolation and characterization of VRC01-class antibodies and the design of immunogens to prime VRC01-class precursors by immunization, the field has yet to elicit VRC01-class antibodies by immunization ([@bib19], [@bib37], [@bib11], [@bib20], [@bib8], [@bib38], [@bib50], [@bib51]). Among other challenges, antibodies of this class can be up to 40% mutated from germline suggesting that during infection, VRC01-class antibodies require long periods of affinity maturation to target the occluded epitope that is surrounded by glycans on the HIV Env trimer ([@bib17], [@bib45]). The glycan at N276 in particular has been previously described to be a key impediment for VRC01-class antibodies to target the CD4bs ([@bib25]), and its removal has been shown to enhance the binding and neutralization activity of antibodies of this class. NGS analysis of VRC01 lineage ontogeny using longitudinal samples collected 5--20 years after infection indeed revealed a complex multi-branched lineage ([@bib55]). However, late sampling only captured lineage sequences that were heavily mutated preventing the reconstruction of the early stages of VRC01 elicitation and maturation. Here, we describe the first complete longitudinal analysis of VRC01-class antibodies affinity maturation from elicitation to acquisition of neutralization breadth in natural infection. The findings also challenge the current strategies relying on glycan-deleted immunogens to select for Ab with glycan avoiding features and suggest that transient direct glycan-binding may help driving affinity maturation toward broad glycan accommodation.

Despite the number of VRC01-class mAbs isolated to date, the field has relied on reverted-germline Abs as templates for vaccine design, which were inferred either by phylogeny of B cell transcripts at a single time point or by reverting the V and J genes and approximating the HCDR3 of mature bnAbs ([@bib19], [@bib37], [@bib20], [@bib11], [@bib8], [@bib38], [@bib5]). Indeed, the uncertainty in determining the PCIN63 lineage precursor light chain despite the availability of contemporaneous samples reveal the importance of small LCDR3 variations on antibody binding, which highlights how sequence approximations could lead to different interpretations of germline antibody binding. We note in the case of PCIN63, both binding to eOD-GT8 and the weak neutralizing activity detected against the M28cH1 glycan-lacking variants by UCA2 chimeric Abs compared to UCA1 suggest but do not formerly validate UCA2 as the true PCIN63 precursor.

Previous studies reported that VRC01-class bnAbs require more time (\>5 years) to develop during infection than bnAbs targeting other Env epitopes (1--3 years) ([@bib29], [@bib34]), a hypothesis supported by the high frequency of SHMs typically found among VRC01-class antibodies ([Figure 1](#fig1){ref-type="fig"}). While there was indeed a late onset for the PCIN63 antibody lineage, neutralization breadth for this lineage was acquired in less than 2 years and isolated mAbs from these time points showed only 10%--15% mutation from germline, which is 2- to 3-fold lower than typical VRC01-class antibodies. PCIN63 is the second VK1-5+ VRC01-subclass bnAb lineage isolated to date ([@bib45]). Together with the recent finding that the VK1-5+ subclass of potential VRC01-class precursors were nearly as common as the most frequent VK3-20+ eOD-GT8-specific B cells in naive donor repertoires ([@bib16]), this suggest (1) that the naive B cells isolated using germline-targeting immunogens may indeed represent true bnAbs precursors and (2) that this particular subclass of bnAbs may serve as a favorable target for vaccine design. Furthermore, evaluation of factors that might have favored the elicitation and focused affinity maturation of the PCIN63 lineage in donor PC063, i.e., frequencies of VRC01-class precursors and biased AID hotspots (see Methods) favoring affinity maturation at key contact residues, showed no significant differences compared to other donors. This suggests that similar focused maturation of PCIN63-like antibodies, with more classical features compared to other bnAbs of this class, might be readily achievable by vaccination.

To inform VRC01-class antibodies targeting vaccine strategies, we thus phylogenetically retraced the evolution of key SHM motifs and functionally tested their contribution to autologous and heterologous neutralization. The observation that PCIN63 lineage heavy chain sampled a greater sequence diversity compared to the light chain is consistent with a stringent selection pressure on the light chain to accommodate glycans surrounding the CD4bs followed by honing of the antibody-epitope interactions through gradual selection of affinity mutations in the heavy chain. Previous studies demonstrated that VRC01-class bnAbs SHM in the LC specifically were critical for the adaptation to the N276- and V5-loop glycans and are required for neutralization breadth. Accordingly, most immunization strategies are designed to prime VRC01-class precursors with immunogens lacking these glycans (eOD-GT8, 426c and donor NIH-45 Env derived molecules). In these studies, the Abs elicited by glycan-lacking priming immunogens typically cannot bind or neutralize Env constructs with the N276-glycan present. The responses are then typically boosted with more native-like Env proteins incrementally incorporating glycans to select for HC and LC mutations that enable binding in the presence of the N276 glycan. However, this strategy has only shown success in models where precursor frequencies are high or when the animal model contains an affinity-mature VRC01-class heavy- or light-chain gene ([@bib8], [@bib11], [@bib20], [@bib38], [@bib50], [@bib51]).

Here we showed that UCA-HC/mature-KC chimeric Ab displayed weak neutralizing activity of the N276-glycan bearing autologous clones but not of their N276-glycan KO counterpart suggesting that direct engagement of the N276-glycan may have facilitated binding. The lineage then affinity matures into two main branches, where one remains dependent on the N276 glycan for binding and the other gaining affinity for the CD4bs epitope in the absence of the N276 glycan. Together with the recent finding that VRC01 inferred GL Ab interacted with the N276-glycan of 426c gp120 core lacking the V1-V2-V3 loops ([@bib6]), these data suggest an alternative vaccine design strategy where the N276-glycan is present on the germline-targeting immunogens at the initial priming stages to select for early intermediates with glycan-binding properties, which could be subsequently boosted with immunogens to affinity mature intermediate precursors to relinquish dependency on the glycan and acquire higher affinity for the CD4bs epitope. A similar strategy was suggested for V2-apex directed Abs upon observation that varying affinities for particular glycoforms were associated with the elicitation of the PCT64 lineage ([@bib30], [@bib42]).

To better understand the putative interactions between PCIN63 Abs and the Env trimer, we constructed an *in silico* model of 12A21 bound to BG505 SOSIP.664 using independently published structures ([@bib24], [@bib56]) ([Figure 6](#fig6){ref-type="fig"}). This model suggests contacts between E62 and CDR2-N57~HC~, and N279 and CDR3-E96~LC~ consistent with the strain-specific N276-glycan dependent variations observed in [Figure 5](#fig5){ref-type="fig"}A. Together with the evidence of early N276-glycan binding and significant toggling of the HCDR2-motif\#2, this model suggests that PCIN63 Abs maturation pathway required a fine balance between glycan avoidance to better access the CD4bs loop and Loop D contact residues, and direct glycan binding to counter lower affinity of early viral intermediates evolving to escape autologous Ab responses. While acquiring a deletion in LCDR1 to avoid the N276-glycan, as seen in most VRC01-class Abs, might be more difficult to reproduce by vaccination, our data suggest that immunization strategies should not focus on glycan-deleted immunogens alone to drive affinity maturation of this lineage.Figure 6Modeling of PCIN63 bnAb Env Contacts Support a Possible Role of Glycan Interactions during Maturation and Lineage CD4bs Immunofocusing(A) *In silico* modeling of 12A21 bound to BG505 SOSIP.664 using the published structures of 12A21 bound to gp120 (PDB ID: [4JPW](pdb:4JPW){#intref0350}) ([@bib24]) and glycosylated BG505 SOSIP.664 bound to 35O22 and PGT122 (PDB ID: [6DE7](pdb:6DE7){#intref0355}) ([@bib56]). Two of the three Env protomers are displayed in shades of gray as transparent surfaces highlighting the CD4bs loop (red), loop D (orange), the V5 loop (yellow) on one protomer and other putative contact residues (cyan) on the second protomer. Glycans surrounding the CD4bs protruding from both protomers are shown as brown spheres and labeled. 12A21 HC and LC residues corresponding to PCIN63 SHM motifs are shown as ribbon and color-coded as defined in [Figure 2](#fig2){ref-type="fig"}B and represented in a diagram (B). Additional motifs in HFR1 (aa19-25 -- pink) and HFWR3 (aa71-76 -- brown) are also highlighted.(B) PC63 infection timeline summary showing the evolution of viral load (red), serum neutralization breadth-potency (score, blue), and overall PCIN63 Ab lineage frequency in the periphery (green line). PCIN63 Ab lineage maturation is further detailed above for each SHM motif as shaded bars from unmutated (white) to fully mature (full motif-specific color) according to the kinetic analysis detailed in [Figure 2](#fig2){ref-type="fig"}. Putative functional impact of SHM motifs maturation regarding contact with Env (gray filled boxes) or internal structural stabilization (open boxes) inferred from the model in (A) are shown color-coded accordingly.

The trajectory for affinity maturation to broadly neutralizing antibodies in natural infection follows complex pathways with many "dead-ends" ([@bib2], [@bib49]) that may be avoided with more focused and targeted rational vaccine design strategies. The isolation of the PCIN63 bnAbs and the identification of their UCA will enable the development of a germline mouse model for a CD4bs lineage known to develop broadly neutralizing activity. Finally, the identification of antibody intermediates and viral sequences will enable the evaluation of candidate boosts to refine immunization schemes that might drive such responses by vaccination.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Monoclonal anti-HIV-1 Env VRC01NIH AIDS Reagent Program; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0010}Cat\# 12033; RRID: [AB_2491019](nif-antibody:AB_2491019){#intref0015}Monoclonal anti-HIV-1 Env minVRC01William Schief, Scripps <schief@scripps.edu>N/AMonoclonal anti-HIV-1 Env 12A12Michel Nussenzweig\
The Rockefeller University <nussen@rockefeller.edu>RRID: [AB_2491040](nif-antibody:AB_2491040){#intref0030}Monoclonal anti-HIV-1 Env 12A21Michel Nussenzweig\
The Rockefeller University <nussen@rockefeller.edu>RRID: [AB_2491036](nif-antibody:AB_2491036){#intref0040}Monoclonal anti-HIV-1 Env min12A21William Schief, Scripps <schief@scripps.edu>N/AMonoclonal anti-HIV-1 Env VRC03NIH AIDS Reagent Program; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0050}Cat\# 12032: RRID: [AB_2491021](nif-antibody:AB_2491021){#intref0055}Monoclonal anti-HIV-1 Env VRC07John R. Mascola, NIH; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0060}N/AMonoclonal anti-HIV-1 Env VRC23John R. Mascola, NIH; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0065}RRID: [AB_2491072](nif-antibody:AB_2491072){#intref0070}Monoclonal anti-HIV-1 Env VRC27John R. Mascola, NIH; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0075}N/AMonoclonal anti-HIV-1 Env VRC-CH31NIH AIDS Reagent Program; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0080}Cat\# 12565; RRID: [AB_2491024](nif-antibody:AB_2491024){#intref0085}Monoclonal anti-HIV-1 Env VRC-PG04Dennis R. Burton, Scripps; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0090}RRID: [AB_2491022](nif-antibody:AB_2491022){#intref0095}Monoclonal anti-HIV-1 Env VRC-PG19John R. Mascola, NIH; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0100}N/AMonoclonal anti-HIV-1 Env VRC-N6NIH AIDS Reagent Program; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0105}Cat\# 12968Monoclonal anti-HIV-1 Env 3BNC117NIH AIDS Reagent Program; [www.hiv.lanl.gov](http://www.hiv.lanl.gov){#intref0110}Cat\# 12474; RRID: [AB_2491033](nif-antibody:AB_2491033){#intref0115}Monoclonal anti-HIV-1 Env PCIN63-UCAs, \_66B to \_77DElise Landais, IAVI (This Paper)N/AMonoclonal inferred germline Ab for anti-HIV-1 Env VRC01, VRC03, VRC07, 12A12, 12A21, 3BNC60, 3BNC117, VRC-PG04, VRC-CH31William Schief, Scripps <schief@scripps.edu>N/APolyclonal anti-HV-1 Env sheep purified Ab D7324Aalto BioreagentsCat \#D7324Alkaline Phosphatase AffiniPure Goat Anti-Human IgG, F(ab')~2~ fragment specificJackson ImmunoResearchCat\# 109-055-097**Bacterial and Virus Strains**37 HIV-1 Env-pseudotyped virusesElise Landais IAVI-NAC (<elandais@iavi.org>)([@bib29])120 HIV-1 Env-pseudotyped virusesD.Montefiori, Duke University (<david.montefiori@duke.edu>)([@bib48])**Biological Samples**PBMC from IAVI Protocol C Donor 63Protocol C, IAVIN/ASerum from IAVI Protocol C Donor 63Protocol C, IAVIN/A**Chemicals, Peptides, and Recombinant Proteins**100mM dNTP setThermo FisherCat\# 10297117293FectinThermo FisherCat\# 12347500AMPure PB BeadsPacific BiosciencesCat\# 100-265-900Complete EDTA free protease inhibitorsRocheCat\# 05056489001**Dynabeads™ MyOne™ Tosylactivated**Thermo FisherCat\# 65502FUGENE 6PromegaCat\# E2692Galanthus nivalis lectin (snow drop), agarose boundVector LabsCat\# AL-1243GeneArt® Seamless Cloning and Assembly Enzyme MixThermo FisherCat\# A14606IgG Elution BufferLuciferase Cell Culture Lysis 5X ReagentPromegaCat\# E1531Phosphatase substrateSigmaCat\# S0942Protein A Sepharose Fast FlowGE healthcareCat\# 17-1279-03QC Lightning Mullti Site-Directed Mutagenesis KitAgilent TechnologiesCat\# 210513Qiaquick PCR purification kitQIAGENCat\# 28106Recombinant HIV-1-gp120 Antigen from 92BR020 Env strainElise Landais, IAVI-NAC (<elandais@iavi.org>)Genebank: AY_669726.1Recombinant HIV-1-gp120 Antigen from JR-CSF Env strainElise Landais, IAVI-NAC (<elandais@iavi.org>)Genebank:\
AY_669718Recombinant HIV-1-gp120 Antigen from PC63 Env clonesThis paperN/ARNase OUTThermo FisherCat\# 10777019SPRI Select ReagentBekman CoulterCat\# B23317SuperScript® III Reverse TranscriptaseThermo FisherCat\# 18080-085**Critical Commercial Assays**DH5a E.ColiBioPioneerCat\# GACC-96PDNA 1200 Analysis KitAgilent TechnologiesCat\# 5067-1508HotStarTaq Plus DNA Polymerase KitQIAGENCat\# 203603Luciferase 1000 Assay SystemPromegaCat\# E4550MiSeq Reagent Kit V3 (600-cycle)IlluminaCat\# MS-102-3003PacBio RS II C3 Sequencing KitPacific BiosciencesCat\# P/N 100-254-800QIAamp Viral RNA Mini KitQIAGENCat\# 52906RNEasy Mini Purification KitQIAGENCat\# 74104SuperScript® III First-Strand Synthesis System for RT-PCRThermo FisherCat\# 18080-051Human Antibody Capture KitGE Healthcare Life SciencesCat\# BR1008394-12% Bis-Tris NuPAGE gel systemThermo FisherCat\# NP0321BOXSMRTbell Template Prep Kit 1.0Pacific BiosciencesCat\# 100-259-100**Deposited Data**PC63 Full-length Env longitudinal sequencesThis PaperGenBank: MK_749242 to MK_749296PCIN63 bnAb lineage HC MiSeq sequencesThis PaperBioProject:\
PRJNA_545346PCIN63-UCAs, \_66B to \_77D heavy chain nt sequencesThis PaperGenBank: MK_749197 to MK_749219PCIN63-UCAs, \_66B to \_77D light chain nt sequencesThis PaperGenBank: MK_749220 to MK749241**Experimental Models: Cell Lines**Human: HEK293TATCCCat\# CRL-3216; RRID: CVCL_0063Human: HEK293S GnT1-ATCCCat\# CRL-3022; RRID: CVCL_A785Human: HeLa-derived TZM-blNIH AIDS Reagent ProgramCat\# 8129-442; RRID: CVCL_B478Human: FreeStyle 293FThermo FisherCat\# R79007; RRID: CVCL_D603**Oligonucleotides**Env-F: GAGCAGAAGACAGTGGCAATGAIntegrated DNA TechnologiesN/AEnv-R: CCACTTGCCACCCATBTTATAGCAIntegrated DNA TechnologiesN/AIgG NGS PrimersIntegrated DNA Technologies([@bib7])**Recombinant DNA**Plasmid pcDNA3.1+Thermo FisherCat\# V790-20Plasmid pSG3DenvNIH AIDS Reagent ProgramCat\# 11051**Software and Algorithms**AbStarBryan Briney (<briney@scripps.edu>), The Scripps Research Instiute<https://github.com/briney/abstar>ClonifyBryan Briney (<briney@scripps.edu>), The Scripps Research Instiute<https://github.com/briney/clonify-python>ETE ToolkitJaime Huerta-Cepa (<jhuerta@crg.es>), Centre for Genomic Regulation, Spain<http://ete.cgenomics.org>FastTreeMorgan N. Price (<MorganNPrice@yahoo.com>) Lawrence Berkely University<http://www.microbesonline.org/fasttree>; RRID:[SCR_015501](rridsoftware:SCR_015501){#intref0185}FigTreeAndrew Rambaut (<andrew.rambaut@zoo.ox.ac.uk>) University of Edinburgh<http://tree.bio.ed.ac.uk/software/figtree/>; RRID:[SCR_008515](rridsoftware:SCR_008515){#intref0200}Full-Length Env Analysis (FLEA) pipelineBen Murrell (<murrellb@gmail.com>), Karolinska Institutet, Sweden.<https://github.com/veg/flea-pipeline/>IMGT/V-QUESTInternational ImMunoGeneTics Information System; Marie-Paule Lefranc (<marie-paule.lefranc@igh.cnrs.fr>), University of Montpellier, France[www.imgt.org](http://www.imgt.org){#intref0220}; RRID: [SCR_012780](rridsoftware:SCR_012780){#intref0225}MAFFTKazutaka Katoh (<kkatoh@kuicr.kyoto-u.ac.jp>) Kyoto University, Japan[http://www.biophys.kyoto-u.ac.jp/∼katoh/programs/align/mafft](http://www.biophys.kyoto-u.ac.jp/%7Ekatoh/programs/align/mafft){#intref0235}; RRID: [SCR_011811](rridsoftware:SCR_011811){#intref0240}Microsoft ExcelMicrosoft CorpRRID: [SCR_016137](rridsoftware:SCR_016137){#intref0245}PacBio SMRTportal Version 2.3Pacific Biosciences<http://www.pacb.com/products-and-services/analytical-software/smrt-analysis/>; RRID: [SCR_002942](rridsoftware:SCR_002942){#intref0255}PANDAseqJosh D. Neufeld (<ac.oolretawu@dlefuenj>) University of Waterloo, Canada<https://github.com/neufeld/pandaseq>; RRID: [SCR_002705](rridsoftware:SCR_002705){#intref0270}PRISM6GraphPad<http://www.graphpad.com/>; RRID: [SCR_002798](rridsoftware:SCR_002798){#intref0280}ProteOn Manager SoftwareBio-RadCat\# 1760200PyMol Molecular Graphics Systems Version 1.5.0.4Schrodinger LLC<https://www.schrodinger.com/pymol>; RRID: [SCR_000305](rridsoftware:SCR_000305){#intref0290}USEARCHRobert C. Edgar (<robert@drive5.com>)<http://www.drive5.com/usearch/>**Other**96S Super Magnet PlateALPAQUACat\# A001322AKTA Pure 25M2GE Healthcare Life SciencesCat\# 29018228C1000 ThermocyclerBio-RadCat\# 1851196FACS ARIA IIIBD BiosciencesCat\# 744763MiSeq SequencerIlluminaN/APacBio RS-II SequencerPacific BiosciencesN/AProteOn XPR36 Protein Interaction Array SystemBio-RadCat\# 1760100ProteOn GLC Sensor ChipBio-RadCat\# 1765011Qubit 3.0 FluorometerThermo FisherCat\# Q33216Sanger Sequencing: bacterial colonies and plasmidsGenewiz<https://www.genewiz.com/>Superdex 200 HiLoad 16/600 columnGE Healthcare Life SciencesCat\# 28989335Synergy H1 Hybrid-Mode Microplate ReaderBiotekN/AVersaMax Microplate ReaderMolecular DevicesN/A

Contact for Reagent and Resources Sharing {#sec4.2}
-----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Elise Landais (<elandais@iavi.org>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human samples {#sec4.3.1}

Donor PC063 was part of the IAVI sponsored Protocol C cohort in sub-Saharan Africa that involved rapid screening of 613 individuals with a recent history of HIV exposure for HIV antibodies in sub-Saharan Africa ([@bib29]). Samples were collected with written, informed consent, and the study was reviewed and approved by institutional Ethics and Research Committees to the participating clinical investigators, namely Susan Allen (Emory University, GA, USA), William Kilembe (University of Zambia, Zambia), Shabir Lakhi (University of Zambia, Zambia), Mubiana Inambao (University of Zambia), Etienne Karita (Republic of Rwanda, Rwanda), Anatoli Kamali (MRC/UVRI Uganda), Eduard J. Sanders (KEMRI, Kenya), Omu Anzala (KAVI and University of Nairobi, Kenya), Vinodh Edward (University of Kwazulu Natal, South Africa), Linda-Gail Bekker (Cape Town University, South Africa), Jill Gilmour (London Imperial College, UK) and Eric Hunter (Emory University, GA, USA) as well as to Elise Landais (Scripps, CA, USA).

Donor PC063 is a female participant enrolled in the Protocol C longitudinal primary infection cohort at 34-year of age, approximately 7 weeks (2 months) after heterosexual infection by a subtype C HIV-1 virus and was identified as one of the top 20% neutralizers, neutralizing up to 85% of viruses on a 37-virus panel ([@bib29]). The neutralizing activity was first detected in the plasma after 5 year of infection and steadily increased to reach a peak at 6 years, neutralizing 79% of viruses from a large panel ([@bib48], [@bib29]). The plasma broadly neutralizing activity was mapped to the CD4 binding site as it was competed by RSC3 and its absorption with rgp120 monomers was competed by b6 and sensitive to the D168R mutation ([@bib29]).

### Cell Lines {#sec4.3.2}

The female HEK-derived 293T, HEK293S N-acetylglucosaminyltransferase I-negative (GnTI−/−), and HeLa-derived TZM-bl cell lines were maintained in complete Dulbecco's Modified Eagle Medium (herein referred to as cDMEM) containing high- glucose Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher), 1X Penicillin-Streptomycin (Pen Strep, Thermo Fisher) and 10% fetal bovine serum (FBS, Gemini Bio Products) at 37°C and 5% CO~2~. FreeStyle HEK-derived 293F cells (Thermo Fisher) were maintained in Freestyle 293 Expression Medium at 37°C and 10% CO~2~ with shaking at 120 RPM.

Methods Details {#sec4.4}
---------------

### Single memory B cell sorting and isolation of PCIN63 monoclonal antibodies {#sec4.4.1}

Sorting of antigen- and epitope-specific memory B cells was performed as previously described ([@bib35], [@bib49], [@bib52], [@bib54]).

Fluorescent-labeled antibodies recognizing cell surface markers were purchased from BD Biosciences. AVI-tagged WT and D368R YU2-gp140-Foldon proteins (plasmid generously provided by Y. Li) were produced, purified, labeled with biotin (Avidity), and coupled to streptavidin-PE, streptavidin-APC (Life Technologies), and streptavidin-BV421 (BD Biosciences), as previously described ([@bib49]). Cells were stained with the Live/Dead Fixable Near-IR Dead Cell Stain Kit (Life Technologies) for 30 min on ice according to the manufacturer's instructions. Cells were then labeled with antibodies for surface markers together with probes for 1 hour in Brilliant Stain buffer (BD Biosciences) on ice. Cells were sorted into individual wells of a 96 well plate containing First Strand buffer containing DTT and RNaseOUT (Life Technologies) using a BD FACSAria III sorter and were immediately sealed and stored at-80°C after sorting each plate.

cDNA was generated from cells sorted into lysis buffer using Superscript III Reverse Transcriptase (Life Technologies) and random hexamers (Gene Link). Nested PCR amplification of heavy- and light-chain variable regions was performed using Multiplex PCR Kit (QIAGEN) and previously described primer sets ([@bib52]). Amplified heavy- and light-chain variable regions were sequenced and subsequently analyzed using IMGT (the International ImMunoGeneTics Information System, [www.imgt.org](http://www.imgt.org){#intref0315}) V-quest ([@bib60]).

Antibodies of interest were cloned into expression vectors ([@bib52]) by re-amplification of sequences using the same primers but modified to introduce homology to the cut ends of the vector, and cloning was performed using the Seamless Cloning and Assembly Enzyme mix (Life Technologies) in expression vectors with the appropriate IgG1, Ig kappa or Ig lambda constant domain. Antibodies incorporating targeted amino acid mutations were generated by Quickchange mutagenesis (Stratagene).

### PCIN63 antibody expression and purification {#sec4.4.2}

Antibodies HC and LC constructs were transiently expressed with the FreeStyle 293 Expression System (Invitrogen). Supernatant was collected after 4-5 days of culture and whole IgGs were purified with Protein A Sepharose (GE Healthcare). Purified proteins purity and integrity checked by SDS--PAGE.

### B cell repertoire next generation sequencing and computational analysis {#sec4.4.3}

RNA was prepared (RNEasy kit, QIAGEN) from total PBMCs (a single of 10 million cells per time point) and was subjected to reverse transcription using barcoding primers that contain unique Ab identifiers as previously described ([@bib7]). The cDNA was then amplified using a mix of gene specific primers containing unique identifiers. Illumina sequencing adapters and sample-specific indexes were added during a second round of PCR. Samples were quantified using fluorometry (Qubit; Life Technologies), pooled at approximately equimolar concentrations, and the sample pool was re-quantified before loading onto an Illumina MiSeq. Paired-end MiSeq reads were merged with PANDAseq ([@bib36]). GL assignment, junction identification, and other basic Ab information was determined using AbStar ([www.github.com/briney/abstar](http://www.github.com/briney/abstar){#intref0320}). Sequences were assigned to clonal lineages using Clonify ([@bib7]). PCIN63 lineage sequences were clustered at 97.5% identity with USEARCH ([@bib12]), and the size of each cluster was recorded. Cluster centroids were used to generate a multiple sequence alignment with MAFFT ([@bib23]), and a tree file was calculated with FastTree using default settings ([@bib41]). The phylogenetic tree was drawn in Python using the ETE Toolkit ([@bib18]).

### AID hotspots analysis {#sec4.4.4}

Frequency and distribution of AID hotspots in PCIN63 lineage HCs, including both mAb and NGS sequences as well as the identified UCA, variable gene region was compared to all IGHV1-2 heavy chain alleles in the IMGT database (<http://www.imgt.org/genedb>). Analysis was performed considering the entire Ab sequence, or each antibody region (CDR1, CDR2, FR1, FR2, FR3) separately. Individual mutations were considered to have occurred in an AID hotspot if the mutated nucleotide fell within a sequence region encoding an AID hotspot motif (RGYW, or the reverse complement WRCY ([@bib43]) in the germline V gene sequence. Separately for each time point, the mean frequency of AID hotspots was determined by counting the number of AID hotspots in each sequence (considering both NGS and mAb sequences) and dividing by the total number of sequences obtained at the time point.

### Single genome amplification (SGA), sequencing and cloning {#sec4.4.5}

HIV-1 RNA was isolated from plasma using the QIAGEN QIAamp Viral RNA kit, and reverse transcribed to cDNA using SuperScript III Reverse Transcriptase (Invitrogen, CA). The envelope genes were amplified from single genome templates ([@bib46]) and amplicons were directly sequenced using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster City, CA) and resolved on an ABI 3100 automated genetic analyzer. The full-length env sequences were assembled and edited using Sequencher v.4.5 software (Genecodes, Ann Arbor, MI).

Selected envelope amplicons were cloned into the expression vector pcDNA 3.1 (directional) (Invitrogen) by re-amplification of SGA first-round products using Pfu Ultra II enzyme (Stratagene) with the EnvM primer, 59-TAGCCCTTCCAGT CCCCCCTTTTCTTTTA-39 ([@bib15]) and directional primer, EnvAstop, 59-CAC CGGCTTAGGCATCTCCTATGGCAGGAAGAA-39 ([@bib27]). Cloned env genes were sequenced to confirm that they exactly matched the sequenced amplicon. Autologous clones were mutated at key residues within the C-strand using the Stratagene QuickChange II kit (Stratagene) as described by the manufacturer. Mutations were confirmed by sequencing. Envelope clones were used to generate single round of replication Env-pseudoviruses as described below.

### Full-length *env* amplification sequencing and computational analysis {#sec4.4.6}

HIV-1 envelope genes were amplified and sequenced as described in [@bib28] ([@bib28]). Briefly, virions were purified from 1-2 mL of plasma at each time point using a sucrose cushion and ultracentrifugation. Viral RNA was extracted (Viral RNA Mini Kit, QIAGEN) and subjected to RT-PCR (SuperScript III First Strand, Thermo Fisher). The cDNA was used as template to generate HIV-1 *env* amplicons, which were then purified (QIAquick, QIAGEN). Replicate PCR reactions for each sample were visualized, quantitated (2100 Bioanalyzer System, Agilent Biosciences) and pooled by sample. Preparation and sequencing of SMRTbell template libraries of approximately 2.6-kb insert size were performed according to the manufacturer's instructions (Pacific Biosciences).

CCS sequences were constructed using the PacBio SMRTportal software (version 2.3). The Full-Length Envelope Analysis (FLEA) pipeline ([@bib58]) was used to error correct these CCS reads, and cluster them into near-identical clusters, inferring High Quality Consensus Sequences (HQCSs) for each cluster. Envelope phylogenies, as well as the dynamics of amino acid frequency evolution, were inferred from these HQCSs. MAFFT (v7.164b ([@bib59]), with manual curation, was used to create a multiple sequence alignment. Gappy regions were manually removed when reconstructing phylogenies, since their alignment is uncertain. Phylogenies were reconstructed with FastTree v2.1 ([@bib41]), and visualized with FigTree (<http://tree.bio.ed.ac.uk/software/figtree/>). Frequency kinetic plots and similar analyses were created with custom Mathematica scripts.

Selected full-length autologous *env* gene sequences were synthesized for representative clones of each time point using GeneArt® gene synthesis services (Life Technologies), then cloned into pcDNA3.1 vector (Life Technologies) for pseudovirus production. Mutagenesis was performed using Quickchange site-directed mutagenesis kit (Agilent Technologies).

### Neutralization assay {#sec4.4.7}

Plasma and monoclonal antibodies neutralizing activity was assessed using single round of replication in TZM-bl target cells, as described previously ([@bib29]) and in absence of DEAE-dextran. Briefly, wild-type (WT) and mutant pseudoviruses were generated by co-transfection of 293T cells with an Env-expressing plasmid and an Env-deficient genomic backbone plasmid (pSG3ΔEnv). Pseudoviruses were harvested 72h post transfection for use in neutralization assays. Pseudoviruses incorporating single amino acid mutations were generated by Quickchange mutagenesis (Stratagene). Plasma samples were heat-inactivated at 56 C for 45min prior to use in neutralization assays.

### Serum adsorptions {#sec4.4.7.1}

Serum adsorptions with antigen-coupled beads were performed using tosyl-activated magnetic beads (Life Technologies), as described previously ([@bib32]). Beads coupling was performed at a ratio of 1mg gp140 per 25mg of beads. Plasma samples were depleted of Abs binding to these proteins through multiple rounds of immunoprecipitation. The depletion of Abs of the desired specificity was confirmed by ELISA prior to using depleted serum in pseudovirus neutralization assays.

### Surface plasmon resonance (SPR) {#sec4.4.8}

SPR experiments were performed on a Proteon XPR36 instrument (Bio-Rad) using GLC sensor chips (Bio-Rad) and 1x HBS buffer (Teknova) supplemented with 1 mg/mL BSA). Chips were prepared using the Human Antibody Capture Kit (GE Healthcare) according to manufacturer's instructions. For kinetic measurements, approximately 100 RUs of the indicated mAbs were captured onto the sensor surface. 4-fold dilution series of the indicated analytes were flowed over the captured mAbs for 120 s, followed by buffer injections for 600 s. After each cycle, surfaces were regenerated by four injections of 3 M magnesium chloride with 180 s contact times. Data were analyzed using the ProteOn Manager software (Bio-Rad). Following interspot and column double referencing, data were fitted to a Langmuir 1:1 binding model or equilibrium binding model as appropriate.

### ELISA assays {#sec4.4.9}

Half-area 96-well ELISA plates were coated overnight at 4C with 50 μL PBS containing 250 ng of compound per well. The D7324 polyclonal sheep Ab (Aalto Bioreagents) targeting the C5 domain of gp120 was also used to capture autologous gp120 from pseudovirus stocks lysed by adding 1% NP40 for 30min at room temperature. The wells were washed four times with PBS containing 0.05% Tween 20 and blocked with 3% BSA at room temperature for 1h. Serial dilutions of sera were then added to the wells, and the plates were incubated at room temperature for 1h. After washing four times, goat anti-human IgG F(ab')2 conjugated to alkaline phosphatase (Pierce), diluted 1:1000 in PBS containing 1% BSA and 0.025% Tween 20, was added to the wells. The plates were incubated at room temperature for 1h, washed four times, and the plates were developed by adding alkaline phosphatase substrate (Sigma) diluted in alkaline phosphatase staining buffer (pH 9.8), according to the manufacturer's instructions. The optical density at 405 nm was read on a microplate reader (Molecular Devices). EC~50~ values were calculated using Prism6 (GraphPad).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

For all mAb/serum pseudovirus neutralization and ELISA assays ([Figures 1](#fig1){ref-type="fig"}C, [4](#fig4){ref-type="fig"}A-B, [5](#fig5){ref-type="fig"}A, S1A, S4B-C, S5, S6, Tables S1-S4) the IC~50~, or concentration of mAb / dilution of serum needed to obtain 50% neutralization against a given pseudovirus, was calculated from the non-linear regression of the neutralization curve. For neutralization assays in which a fold-change in IC~50~ imparted by a particular virus mutant or virus treatment was reported ([Figures 5](#fig5){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}), the IC~50~ obtained for one virus/assay condition was divided by the IC~50~ obtained for the other virus/assay condition, as indicated in the figure legends. All neutralization and ELISA assays were repeated at least twice, and data shown are from representative experiments.

SPR measurements ([Figure 3](#fig3){ref-type="fig"}B) were taken over two independent experiments, and data shown are from representative experiments.

Data and Code Availability {#sec4.6}
--------------------------

The accession numbers for the PCIN63-UCA and PCIN63-66A to PCIN63-77F heavy chain sequences reported in this paper are GenBank: MK_749197, MK_749198, MK_749199, MK_749200, MK_749201, MK_749202, MK_749203, MK_749204, MK_749205, MK_749206, MK_749207, MK_749208, MK_749209, MK_749210, MK_749211, MK_749212, MK_749213, MK_749214, MK_749215, MK_749216, MK_749217, MK_749218, MK_749219.

The accession numbers for the PCIN63-UCA and PCIN63-66A to PCIN63-77F light chain sequences reported in this paper are GenBank: MK_749220, MK_749221, MK_749222, MK_749223, MK_749224, MK_749225, MK_749226, MK_749227, MK_749228, MK_749229, MK_749230, MK_749231, MK_749232, MK_749233, MK_749234, MK_749235, MK_749236, MK_749237, MK_749238, MK_749239, MK_749240, MK_749241.

The MiSeq PCIN63 Ab lineage heavy and light chain NGS dataset are publicly available online through BioProject: PRJNA545346.

The accession numbers for the PC63 Env clones and HQCS reported in this paper are GenBank: MK_749242, MK_749243, MK_749244, MK_749245, MK_749246, MK_749247, MK_749248, MK_749249, MK_749250, MK_749251, MK_749252, MK_749253, MK_749254, MK_749255, MK_749256, MK_749257, MK_749258, MK_749259, MK_749260, MK_749261, MK_749262, MK_749263, MK_749264, MK_749265, MK_749266, MK_749267, MK_749268, MK_749269, MK_749270, MK_749271, MK_749272, MK_749273, MK_749274, MK_749275, MK_749276, MK_749277, MK_749278, MK_749279, MK_749280, MK_749281, MK_749282, MK_749283, MK_749284, MK_749285, MK_749286, MK_749287, MK_749288, MK_749289, MK_749290, MK_749291, MK_749292, MK_749293, MK_749294, MK_749295, MK_749296.
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